Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries

(2014) M. Castanheira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Proliferation and significance of clinically relevant β-lactamases

(2013) Karen Bush   Annals of the New York Academy of Sciences

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

(2013) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

(2013) Brian VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

(2013) H. W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012

(2013) L. Dortet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study

(2013) Mikhail V Edelstein et al.   LANCET INFECTIOUS DISEASES

In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice

(2012) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Influence of Multidrug Resistance and Appropriate Empirical Therapy on the 30-Day Mortality Rate of Pseudomonas aeruginosa Bacteremia

(2012) Laura Morata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

(2012) R. Cantón et al.   CLINICAL MICROBIOLOGY AND INFECTION

Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

(2012) L. S. Tzouvelekis et al.   CLINICAL MICROBIOLOGY REVIEWS

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

(2011) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infections–Proceedings and Data From the Gram-Negative Resistance Summit

(2011) Marin H. Kollef et al.   CLINICAL INFECTIOUS DISEASES

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

The CTX-M Conundrum: Dissemination of Plasmids and Escherichia coli Clones

(2011) Umaer Naseer et al.   Microbial Drug Resistance

Pseudomonas aeruginosa: all roads lead to resistance

(2011) Elena B.M. Breidenstein et al.   TRENDS IN MICROBIOLOGY

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

(2009) C. C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy

(2009) Alexandre P Zavascki et al.   Expert Review of Anti-Infective Therapy